Your search matched 1 results
More than 20 years ago, Gleevec ushered in a therapeutic revolution in oncology based on a relatively simple premise: If cancer cells are “addicted” to oncogenic mutations, targeting the troublesome protein might provide long-lasting disease control.
Already have a RSS feed reader?
